Mayank Mamtani

Robert LeBoyer

James Molloy

Joseph Pantginis

Louise Chen

- PDS Biotechnology Corporation filed an 8-K on **August 25, 2025**, to announce the update of its corporate presentation deck.  **[1472091_0001140361-25-032503_ef20054434_8k.htm:0]** **[1472091_0001140361-25-032503_ef20054434_8k.htm:1]** 
- The updated presentation highlights **positive Phase 2 trial results** for **PDS0101** in HPV16+ 1L R/M HNSCC, showing a **median overall survival of 39.3 months**.  **[1472091_0001140361-25-032503_ef20054434_ex99-1.htm:4]** **[1472091_0001140361-25-032503_ef20054434_ex99-1.htm:5]** **[1472091_0001140361-25-032503_ef20054434_ex99-1.htm:7]** 
- **PDS0101** is currently in a **pivotal Phase 3 clinical trial (VERSATILE-003)** for 1L R/M HPV16+ HNSCC, with enrollment anticipated to be complete in **1H 2026**.  **[1472091_0001140361-25-032503_ef20054434_ex99-1.htm:4]** **[1472091_0001140361-25-032503_ef20054434_ex99-1.htm:5]** **[1472091_0001140361-25-032503_ef20054434_ex99-1.htm:7]** 
- The company also detailed its **PDS01ADC pipeline**, which includes Phase 2 investigator-initiated trials for other cancer indications.  **[1472091_0001140361-25-032503_ef20054434_ex99-1.htm:4]** **[1472091_0001140361-25-032503_ef20054434_ex99-1.htm:7]**

PDS Biotechnology (PDSB)